Physician profile
Thomas Tseng
NPI 1912017211
$11,804.44
in general payments reported to CMS, 2019-2025
42 companies · $885 in 2025
The $885 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,749 · 2020: $1,652 · 2021: $2,058 · 2022: $1,583 · 2023: $2,219 · 2024: $1,658 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,762.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,893.54 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $1,161.72 | 2019-2025 | Vraylar, Linzess, Creon |
| Astellas Pharma US INC | $962.00 | 2019-2023 | Myrbetriq |
| Amarin Pharma, INC. | $831.32 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $628.95 | 2019-2024 | Jardiance |
| Nestle Healthcare Nutrition INC. | $578.12 | 2020-2023 | |
| Gilead Sciences, INC. | $481.71 | 2019-2024 | Vemlidy |
| Astrazeneca Pharmaceuticals Lp | $363.95 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $331.79 | 2019-2022 | |
| Allergan, INC. | $325.23 | 2019-2020 | |
| Lilly USA, LLC | $306.89 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $267.05 | 2019-2025 | |
| Cmp Pharma, INC. | $237.31 | 2023 | Norliqva |
| Aimmune Therapeutics, INC. | $161.59 | 2024-2025 | Zenpep |
| Otsuka America Pharmaceutical, INC. | $148.59 | 2023 | Rexulti |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $142.44 | 2019-2024 | |
| Vivus LLC | $127.51 | 2023-2025 | Pancreaze |
| Teva Pharmaceuticals USA, INC. | $121.88 | 2024 | Austedo Xr |
| Almatica Pharma LLC | $120.67 | 2022-2024 | Loreev Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.48 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $118.80 | 2022-2024 | |
| Novo Nordisk INC | $110.17 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $103.22 | 2023-2025 | Gvoke Hypopen |
| Biogen, INC. | $96.77 | 2020-2022 | |
| Redhill Biopharma INC. | $96.22 | 2020-2022 | |
| Radius Health, INC. | $95.40 | 2020-2025 | Tymlos |
| Shield Therapeutics INC | $91.17 | 2022-2025 | Accrufer |
| Glaxosmithkline, LLC. | $90.52 | 2023-2025 | Arexvy, Shingrix |
| Corium, LLC | $76.05 | 2023 | Adlarity |
| Ironwood Pharmaceuticals, INC | $76.01 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $69.83 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $64.13 | 2019 | |
| Lundbeck LLC | $57.97 | 2023-2024 | Rexulti |
| Genentech USA, INC. | $55.21 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $55.10 | 2024-2025 | |
| Exact Sciences Corporation | $42.11 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $40.55 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $39.55 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.96 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $34.19 | 2021 | |
| Sun Pharmaceutical Industries INC. | $27.19 | 2021 | |
| Dexcom, INC. | $17.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Tseng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.